Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-07-03 00:00:00 ET · period of report 2025-07-01 · accession 0001415889-25-019321 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-03 | 2025-07-01 | SPRY | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +15.0K | 25.3K | +145% | +$22.5K |
| D | 2025-07-03 | 2025-07-01 | SPRY | Karas Eric | Chief Commercial Off | S - Sale+OE | $16.99 | -15.0K | 10.3K | -59% | -$254.8K |
| D | 2025-07-03 | 2025-07-01 | SPRY | Karas Eric | Chief Commercial Off | M - OptEx | $0.00 | -15.0K | 544.6K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-01 | M | A | 15,000 | $1.50 | 25,315 | D | — | — | (F1) Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025. |
| 2 | Common | Common Stock | 2025-07-01 | S | D | 15,000 | $16.99 | 10,315 | D | — | — | (F3) The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-07-01 | M | D | 15,000 | $0.00 | 544,588 | D | $1.50 · — to 2032-05-23 | 15,000 Common Stock | (F4) Immediately exercisable. |